Catabasis Pharma Bags $8M More for Series A


Massachusetts-based Catabasis Pharmaceuticals raised an additional $8 million in its Series A financing, now bringing its total funding for the round to $47.6 million. The company is developing an omega-3 conjugated compound for patients with severe hypertriglyceridemia. SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures all participated in the funding.

PRESS RELEASE:

Today, Cambridge-based Catabasis Pharmaceuticals announced it has received an additional $8 million in Series A financing, bringing the total amount raised in its Series A to $47.6 million.
The new funding will be used to accelerate the development of CAT-2003, the company’s omega-3 conjugated compound for patients with severe hypertriglyceridemia.
Very high triglyceride levels, also known as severe hypertriglyceridemia, are a risk factor for acute pancreatitis. Jill C. Milne, Ph.D., chief executive officer and co-founder of Catabasis is available for interviews to discuss the additional funding and the progress being made with CAT-2003.
All current investors participated in the financing, including SV Life Sciences, Clarus Ventures, MedImmune Ventures and Advanced Technology Ventures.
In October, Catabasis announced the initiation of a clinical trial of CAT-1004, a new chemical entity that is a conjugate of the essential omega-3 fatty acid docosahexaenoic acid (DHA) and salicylate. The compound targets inflammation and is being developed to treat patients with type 2 diabetes. Currently, there are no drugs on the market for diabetes that are directed at inflammation.

Find new deal opportunities, super-charge your fundraising efforts and track top managers with VCJ. Get your FREE trial! Or subscribe now!

Do you want exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more? Get your FREE trial to Buyouts! Or subscribe now!

Take your pick!

  • Buyouts delivers exclusive news and analysis about private equity deals, fundraising, top-quartile managers and more. Get your FREE trial or subscribe now.
  • VC Journal provides exclusive news and analysis about venture capital deals, fundraising, top-quartile investors and more. Get your FREE trial or subscribe now.
DON'T MISS IT! Now in its 10th year, PartnerConnect Midwest is bringing you 300 attendees, over 400 private ExecConnect meetings between LPs and GPs, and three insightful tracks including Buyouts Funds, Buyouts Deals and Co-Investments. REGISTER TODAY!